Tag - MYNZ

Developments

Mainz Biomed submits application for FDA breakthrough device designation for CRC product

Mainz Biomed (NASDAQ:MYNZ) announced that it has submitted an application to the FDA requesting breakthrough device designation for its non-invasive, next-generation colorectal cancer (CRC) screening test, which...

July 9, 2024

Markets

Cantor starts Mainz Biomed at OW; PT $15

Cantor Fitzgerald launched coverage of Mainz Biomed B.V. (NASDAQ:MYNZ) with an “overweight” rating and 12-month price target of $15. The stock closed at $6.63 on Oct. 24. MYNZ develops market-ready molecular genetic...

October 25, 2022

Tag - MYNZ

Mainz Biomed submits application for FDA breakthrough device designation for CRC product

Cantor starts Mainz Biomed at OW; PT $15

General

More